Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In the literature: February 2019.
Insa A, Gambardella V, Cervantes A. Insa A, et al. ESMO Open. 2019 Feb 13;4(1):e000490. doi: 10.1136/esmoopen-2019-000490. eCollection 2019. ESMO Open. 2019. PMID: 30962957 Free PMC article. No abstract available.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Garon EB, et al. N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891174 Free article. Clinical Trial.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Soria JC, et al. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Escudero-Vilaplana V, Collado-Borrell R, De Castro J, Insa A, Martínez A, Fernández E, Sullivan I, Flores A, Arrabal N, Carcedo D, Manzaneque A. Escudero-Vilaplana V, et al. Among authors: insa a. J Med Econ. 2023 Jan-Dec;26(1):445-453. doi: 10.1080/13696998.2023.2188844. J Med Econ. 2023. PMID: 36883193 Free article.
In the literature: December 2019.
Gambardella V, Insa A, Cejalvo JM, Cervantes A. Gambardella V, et al. Among authors: insa a. ESMO Open. 2020 Jan;5(1):e000642. doi: 10.1136/esmoopen-2019-000642. ESMO Open. 2020. PMID: 31958287 Free PMC article. No abstract available.
Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation.
Martínez MT, Montón-Bueno J, Simon S, Ortega B, Moragon S, Roselló S, Insa A, Navarro J, Sanmartín A, Julve A, Buch E, Peña A, Franco J, Martínez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. Martínez MT, et al. Among authors: insa a. ESMO Open. 2021 Jun;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. Epub 2021 May 11. ESMO Open. 2021. PMID: 33989988 Free PMC article.
Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme.
Martínez MT, Moragon S, Ortega-Morillo B, Montón-Bueno J, Simon S, Roselló S, Insa A, Viala A, Navarro J, Sanmartín A, Fluixá C, Julve A, Soriano D, Buch E, Peña A, Franco J, Martínez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Martínez MT, et al. Among authors: insa a. Cancer Control. 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. Cancer Control. 2022. PMID: 36355430 Free PMC article.
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.
Michels S, Massutí B, Vasyliv I, Stratmann J, Frank J, Adams A, Felip E, Grohé C, Rodriguez-Abreu D, Bischoff H, Carcereny I Costa E, Corral J, Pereira E, Fassunke J, Fischer RN, Insa A, Koleczko S, Nogova L, Reck M, Reutter T, Riedel R, Schaufler D, Scheffler M, Weisthoff M, Provencio M, Merkelbach-Bruse S, Hellmich M, Sebastian M, Büttner R, Persigehl T, Rosell R, Wolf J. Michels S, et al. Among authors: insa a. ESMO Open. 2024 Feb;9(2):102237. doi: 10.1016/j.esmoop.2024.102237. Epub 2024 Feb 12. ESMO Open. 2024. PMID: 38350336 Free PMC article.
58 results